With Amgen’s stock down and the outlook still pretty grim for the company’s anemia drugs, CEO Kevin Sharer took his licks at yesterday’s annual meeting. The LA Times was there, and reports a few choice lines in today’s paper.
“You say you are looking out for the best interest of shareholders. I don’t believe you are,” [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment